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We have identified a gene, SHR5, in a screen for extragenic suppressors of the hyperactive RAS2Val-19
mutation in the budding yeast Saccharomyces cerevisiae. SHR5 was cloned, sequenced, and found to encode a
23-kDa protein not significantly homologous to other proteins in the current data bases. Genetic evidence
arguing that Shr5 operates at the level of Ras is presented. We tested whether SHR5, like previously isolated
suppressors of hyperactivated RAS2, acts by affecting the membrane attachment and/or posttranslational
modification of Ras proteins. We found that less Ras protein is attached to the membrane in shr5mutants than
in wild-type cells and that the Ras proteins are markedly underpalmitoylated, suggesting that Shr5 is involved
in palmitoylation of Ras proteins. However, shr5null mutants exhibit normal palmitoyltransferase activity
measured in vitro. Further, shr5null mutations attenuate Ras function in cells containing mutant Ras2 proteins
that are not palmitoylated or farnesylated. We conclude that SHR5 encodes a protein that participates in the
membrane localization of Ras but also interacts in vivo with completely unprocessed and cytosolic Ras
proteins.
In the budding yeast Saccharomyces cerevisiae, Ras (31, 44)
is regulated positively by the gene product of CDC25 (5, 8),
which encodes its guanine nucleotide exchange factor, and
negatively by the gene products of IRA1 and IRA2 (54), which
encode homologs of mammalian GTPase-activating proteins
(GAPs). Ras is involved in the regulation of nutrient sensing
and mitotic growth through the adenylyl cyclase pathway (4,
58). Hyperactivation of the Ras-adenylyl cyclase pathway in S.
cerevisiae results in several phenotypes, most notably an inabil-
ity to arrest at G1, heat shock sensitivity, nutrient starvation
sensitivity, and an inability to sporulate (32, 58). Although the
adenylyl cyclase pathway accounts for much of the Ras effects
in S. cerevisiae, there is genetic evidence for an alternate Ras
pathway that remains, at present, ill-defined (60).
In both yeasts and mammals, a progression of modifications
of the CAAX motif at the carboxyl terminus of RAS is critical
for protein-protein interactions and membrane localization
(for reviews, see references 13, 14, 34, 37, 39, and 42). The
initial modification of the CAAX motif is the isoprenylation
(farnesylation) of the cysteine (26), which is followed by pro-
teolytic cleavage of the last three amino acids and subsequent
carboxy methylation of the terminal polyisoprenylated cysteine
(25). For many Ras proteins (26), acylation (palmitoylation) of
the penultimate cysteine (61) results in the fully matured form
of the protein. Whereas farnesylation of mammalian Ras has
been shown to be critical for its function (11, 33), the role of
palmitoylation appears to be limited to the efficient attachment
of Ras proteins to membranes (26). Similarly, farnesylation of
yeast Ras2 protein significantly increases its ability to activate
and associate with adenylyl cyclase, whereas palmitoylation
promotes its effective membrane localization (35) and its spe-
cific targeting to the plasma membrane (43).
Elements involved in the effector function, regulation, and
modification of Ras proteins have previously been identified in
this and other laboratories by selection for mutants that sup-
press RAS2Val-19 function in S. cerevisiae. Suppressor muta-
tions in CYR1, which encodes adenylyl cyclase (30), and CAP,
which encodes a protein that binds to adenylyl cyclase (16),
were isolated. Suppressors of RAS2Val-19 also led to the initial
identification of genes involved in Ras protein modification,
RAM1 and RAM2, that encode the subunits of the het-
erodimeric Ras farnesyltransferase (19, 22, 27, 45, 52). Here,
we present genetic and biochemical characterization of an-
other gene that we identified from analysis of phenotypic re-
vertants of a RAS2Val-19 mutant. We designate this gene SHR5
(suppressor of hyperactive RAS2Val-19), since it represents the
fifth gene identified as an extragenic suppressor of RAS2Val-19.
MATERIALS AND METHODS
Yeast strains and plasmids. The yeast strains and plasmids used in this study
are described in Table 1. Various strains were disrupted with plasmid pDF-H3 or
pDF-L2 as described below. BCY1 in strain SPDFB was disrupted with plasmid
pbcy1::URA3 (56). Construction of SHR5 plasmids is described below.
Isolation of extragenic suppressors of RAS2Val-19. S. cerevisiae strains carrying
an activated RAS2Val-19 allele do not become heat shock resistant upon reaching
stationary phase (50). We exploited this phenotypic difference to isolate rever-
tants of the ras1null RAS2Val-19 strain PT1-6. A genetic screen previously used for
isolation of the ram1 and ram2 mutants (27, 45) was modified as follows. Indi-
vidual colonies were incubated in liquid medium at saturation at 308C for 4 days
and then heat shocked for 30 min at 508C in glass tubes. The heat-shocked
cultures were then plated, and surviving colonies were isolated and retested for
heat shock resistance by a plate assay (50).
Isolation of SHR5 and genetic manipulations. RAS2Val-19-containing strains
are more heat shock resistant when they reach stationary phase if they contain an
shr5 allele. Therefore, the gene for SHR5 was isolated by selection for reversal of
the heat shock resistance in the RAS2Val-19 shr5 strain RS44-5B. Briefly, these
cells were transformed with an S. cerevisiae genomic DNA library constructed in
the centromeric vector YCp50 (libraries AB493, AB494, AB495, and AB496
[kindly provided by Mark Rose]), and approximately 200 transformants per plate
were grown on selective medium. One week later, 15,000 colonies were repli-
cated onto plates previously equilibrated to 558C for heat shocks of 5- and 10-min
* Corresponding author. Mailing address: Cold Spring Harbor Lab-
oratory, P.O. Box 100, Cold Spring Harbor, NY 11724.
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durations. Transformants that recovered their sensitivity to heat shock were
isolated. Plasmid DNA was isolated from these cells and tested for its ability to
rescue heat shock sensitivity when it was retransformed into strain RS44-5B.
Plasmids that rescued shr5 were mapped by restriction analysis and subcloned
into the yeast plasmid pRS416 (53). The ability of subclones to rescue shr5
allowed localization of the gene to a 1.8-kb fragment which was sequenced
bidirectionally by the Sanger method (Fig. 1) (49). The open reading frame
(ORF) encoding SHR5 was amplified by PCR using the oligonucleotide pair
59-TACTCAATCTAACCCGTCGACGATGTGC-39 and 59-CACGATAAAGC
CCTGGTCGACCCATAAA-39, which contain internal SalI sites (in boldface), to
facilitate cloning into identical sites in the S. cerevisiae expression plasmids
pAD4D (2) and pAD54 (15), creating plasmids pAD4D-SHR5 and pAD54-
SHR5, respectively.
Plasmids designed for a one-step gene disruption (47) of SHR5 were con-
structed that contained deletions from the XbaI site to the BsaBI site in the ORF
of SHR5, with insertions of a 1.8-kb HIS3 fragment (28), creating plasmid
pDF-H3, or of a 2-kb LEU2 fragment (28), creating plasmid pDF-L2. This
effectively deleted all but the first four amino acids of Shr5. SHR5 was disrupted
by transformation of various yeast strains with a SalI-EcoRI fragment derived
from pDF-H3 or a SphI-SacI fragment derived from pDF-L2. Successful disrup-
tions were confirmed by PCR using an oligonucleotide primer pair that flanked
the deletion.
Integrative mapping was performed by mating SPDFa (MATa shr5::HIS3) and
strain SN12 (MATa shr5) transformed with plasmid YEp13-PDE2.2 (50). High-
level expression of a yeast phosphodiesterase gene allows sporulation in diploids
that express hyperactive RAS2Val-19 (58).
Heat shock and temperature sensitivity assays. Heat shock assays (50, 58)
were performed by replica plating patches of cells that had been starved for 2 to
3 days onto plates that were preheated for 1 h at 558C and then by incubation for
2.5, 5, and 10 min at the same temperature and transfer to 308C for 2 to 3 days.
Temperature sensitivity assays were performed by replica plating patches of cells
onto plates that were then incubated at the temperatures indicated in the re-
spective figures.
Metabolic labeling of Ras proteins with [3H]palmitic acid.Metabolic labeling
FIG. 1. Sequence of the SHR5 ORF. The start and stop codons are in
boldface. Multiple in-frame stop codons occur upstream of the initial ATG. The
GenBank accession number for SHR5 is U18313. *, termination codon.
TABLE 1. Strains and plasmids used in this study
Strain or plasmid Genotype or description Reference or source
Strains
IR-1 MATa leu2 ura3 his3 trp1 ade8 can1 ira1::HIS3 2
IR1DF MATa leu2 ura3 his3 trp1 ade8 can1 ira1::HIS3 shr5::LEU2 This paper
IR-2.1 MATa leu2 ura3 his3 trp1 ade8 can1 ira2::URA3 1
IR2DF MATa leu2 ura3 his3 trp1 ade8 can1 ira2::URA3 shr5::LEU2 This paper
KP-2 MATa leu2 ura3 his3 trp1 ade8 can1 ras2::URA3 32, 58
KPDF MATa leu2 ura3 his3 trp1 ade8 can1 ras2::URA3 shr5::HIS3 This paper
LI-1-3A MATa leu2 ura3 his3 trp1 ade8 ras1::TRP1 RAS2Ser-318 S. Powers
LIDF MATa leu2 ura3 his3 trp1 ade8 ras1::TRP1 RAS2Ser-318 shr5::HIS3 This paper
PT1-6 MATa leu2 ura3 his3 trp1 ade8 can1 RAS2Val-19 ras1::URA3 45
RS44-5B MATa ura3 his3 trp1 ade8 can1 RAS2Val-19 shr5-1 S. Powers
RS81-1B MATa leu2 ura3 his3 trp1 ade8 can1 RAS2::URA3 shr5::HIS3 S. Powers
SN12 MATa leu2 ura3 his3 trp1 ade8 RAS2Val-19 ras1::URA3 shr5-1 S. Powers
SN31 MATa leu2 ura3 his3 trp1 ade8 RAS2Val-19 ras1::URA3 shr5-2 S. Powers
SN38 MATa leu2 ura3 his3 trp1 ade8 RAS2Val-19 ras1::URA3 shr5-3 This paper
SP1 MATa leu2 ura3 his3 trp1 ade8 can1 58
SPDF MATa leu2 ura3 his3 trp1 ade8 can1 shr5::HIS3 This paper
SPDFa MATa leu2 ura3 his3 trp1 ade8 can1 shr5::HIS3 This paper
SPDFB MATa leu2 ura3 his3 trp1 ade8 can1 shr5::HIS3 bcy1::URA3 This paper
ST-1 MATa leu2 ura3 his3 trp1 ade8 can1 ras1::URA3 32, 58
ST1DF MATa leu2 ura3 his3 trp1 ade8 can1 ras1::URA3 shr5::HIS3 This paper
STS1 MATa leu2 ura3 his3 trp1 ade8 can1 ras2ts ras1::URA3 10, 46
STS1DF MATa leu2 ura3 his3 trp1 ade8 can1 ras2ts ras1::URA3 shr5::HIS3 This paper
STS3 MATa leu2 ura3 his3 trp1 ade8 can1 ras1::URA3 ras2Val-19Phe-319 S. Powers
STS3DF MATa leu2 ura3 his3 trp1 ade8 can1 ras1::URA3 ras2Val-19Phe-319 shr5::HIS3 This paper
T158-5A1 MATa leu2 ura3 his3 trp1 ade8 cyr::URA3 yEp(ADE8)SCH9 Takashi Toda
T158DF MATa leu2 ura3 his3 trp1 ade8 cyr::URA3 shr5::HIS3 yEp(ADE8)SCH9 This paper
TK161-R2V MATa leu2 ura3 his3 trp1 ade8 can1 RAS2Val-19 32
TKDF MATa leu2 ura3 his3 trp1 ade8 can1 RAS2Val-19 shr5::HIS3 This paper
TMRV-25 MATa leu2 ura3 his3 trp1 ade8 can1 RAS2Val-19 cdc25::URA3 5
TMDF MATa leu2 ura3 his3 trp1 ade8 can1 RAS2Val-19 cdc25::URA3 shr5::HIS3 This paper
Plasmids
pAD4D LEU2; ADH promoter 2
pAD54 Epitope-tagged expression vector 15
pAD4D-SHR5 SHR5 cDNA expression This paper
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of Ras proteins with [3H]palmitic acid was performed exactly as described by
Powers et al. (45). The labeled Ras proteins were detected with antibody Y13-
259 (20) as the primary antibody. Colorimetric detection of Ras proteins was
quantitated by densitometry.
Fractionation of yeast extracts and immunoblotting of epitope-tagged Shr5
proteins. One-hundred-milliliter cultures of SP1 cells transformed with plasmids
expressing either Shr5, Ste18, or GST, each as hemagglutinin HA1 epitope-
tagged (15, 23, 62) proteins, were grown in synthetic medium with galactose to
late log phase. The cells were pelleted and washed with ice-cold buffer E (0.3 M
sorbitol, 0.1 M NaCl, 5 mMMgCl2, 10 mM Tris [pH 7.4]), resuspended in 500 ml
of buffer E containing 1 mM phenylmethylsulfonyl fluoride and 1 mg of aprotinin
per ml, and lysed with glass beads and vortexing. The lysate was cleared by
centrifugation at 500 3 g for 10 min to obtain the supernatant and pellet
fractions. Fifteen microliters of each fraction was mixed with 15 ml of 23
Laemmli loading buffer (36), subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), and transferred to nitrocellulose paper. Im-
munoblotting with 12CA5 antibody (41) was performed as described elsewhere
(15) and visualized with enhanced chemiluminescence reagents (Amersham,
Arlington Heights, Ill.).
In vitro palmitoylation assay. In vitro acylation (palmitoylation) assays were
performed essentially as described by Gutierrez and Magee (24) in a buffer
containing 5 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid (HEPES;
pH 7.4), 2 mM MgCl2, 1 mM ethylene glycol-bis (b-aminoethyl ether)-N,N,
N9,N9-tetraacetic acid (EGTA), 10 mM NaCl, 130 mM KCl, 1 mM ATP, 200 mM
coenzyme A, 1 mM dithiothreitol, 10 mCi of [3H]palmitate {[9,1023H(N)]
palmitic acid; 47 Ci/mmol; DuPont-New England Nuclear, Boston, Mass.}, and
5 mg of yeast extract in a total volume of 100 ml. Incubations were carried out for
1 h at 378C and stopped by the addition of 500 ml of cold acetone. Acetone
precipitates were resuspended in Laemmli loading buffer (36) containing 100
mM dithiothreitol and were subjected to electrophoresis in SDS-12% PAGE.
The gels were treated with ENTENSIFY (DuPont-New England Nuclear) ac-
cording to the directions supplied by the manufacturer and were exposed directly
to Kodak XAR-5 film at 2858C.
RESULTS
Identification of shr5 as an extragenic suppressor of
RAS2Val-19 and cloning of the wild-type SHR5 gene. RAS2Val-19
mutants, unlike wild-type yeast cells, are not heat shock resis-
tant upon reaching stationary phase (50). We exploited this
phenotypic difference to isolate revertants from the ras1null
RAS2Val-19 mutant strain PT1-6 (45). Sixty-four independently
derived revertants were obtained in a heat shock screen as
described in Materials and Methods. On the basis of comple-
mentation analysis, 55 of 64 of these revertants were due to
either recessive mutations in the adenylyl cyclase gene or in-
tragenic suppressor mutations in the RAS2Val-19 gene itself.
Three of the remaining nine revertants formed a single
complementation group, supF, that we now call shr5. In plate
assays, RAS2Val-19 shr5 revertants were not as heat shock re-
sistant as wild-type cells and, unlike wild-type cells, had low
levels of glycogen (29). By these criteria and in contrast to
ram1 (45), ram2 (45), or cyr1 (30) suppressor mutations, shr5 is
only a partial suppressor of RAS2Val-19.
The SHR5 gene was isolated by screening a centromeric
genomic DNA library for plasmids that reversed the heat shock
resistance of RAS2Val-19 shr5 cells. One of 15,000 transfor-
mants that reversed heat shock resistance in a plasmid-depen-
dent manner was isolated. Plasmid pSHR5-19.7 was recovered
from the revertant and contained a 19-kbp insert. Deletion
analysis led to the subcloning of a 1.8-kb MscI-ClaI fragment
that could rescue shr5. The fragment was completely se-
quenced (Fig. 1), and a 765-bp ORF was identified. In-frame
stop codons were found upstream of the first ATG. The ORF
can encode a product of about 26.7 kDa (see below). Compar-
ison with available databases failed to identify significant ho-
mology to other proteins.
Several genetic criteria indicating that the isolated gene was
indeed SHR5 were satisfied. First, plasmids were constructed
for the disruption of SHR5. Disruption of SHR5 in a
RAS2Val-19 strain resulted in heat shock-resistant cells (Fig. 2,
rows 3 and 4). Disruption of SHR5 in a wild-type strain had no
effects on its heat shock sensitivity (Fig. 2, rows 1 and 2).
Second, we found that expression of the predicted ORF from
FIG. 2. Reversal of heat shock sensitivity by SHR5 disruption and reconsti-
tution of heat shock sensitivity by expression of the SHR5 cDNA. The SHR5
strain is wild-type SP1 (row 1); the shr52 strain is SPDF (row 2); the RAS2Val-19
strain is TK161-R2V (row 3); the RAS2Val-19 shr5null strain is TKDF (rows 4 and
5). The rescue of the shr5 disruption in strain TKDF (row 4) was with plasmid
pAD54-SHR5, expressing a cDNA for SHR5 (row 5). Cells were heat shocked at
558C for 10 min (109).
TABLE 1—Continued
Strain or plasmid Genotype or description Reference or source
pAD54-SHR5 Epitope-tagged SHR5 expression This paper
pbcy1::URA3 BCY1 disruption vector 56
pRS416 URA3; centromeric vector 53
pSHR5-19.7 SHR5 in vector YCp50 This paper
pDF-H3 SHR5 disruption by HIS3 This paper
pDF-L2 SHR5 disruption by LEU2 This paper
YCplac22 TRP1; CEN 21
YCp22-SHR5 SHR5 This paper
YEp112 TRP1; 2mm 21
YEp112-RAS2Val-19 RAS2Val-19 This paper
YEp13 LEU2; 2mm 3
YEp13-CDC25 Guanine nucleotide exchange factor 8
YEp13-CYR1-11 Adenylyl cyclase 30
YEp13-PDE2.2 Phosphodiesterase 50
YEp13-SCH9 cAMP-related protein kinase 55
YEp13-TPK1 cAMP-dependent protein kinase 57
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the yeast alcohol dehydrogenase (ADH) promoter can recon-
stitute the heat shock sensitivity of all shr5 alleles (strains
SN12, SN31, and SN38) (29) as well as of the shr5null strains
(Fig. 2, rows 4 and 5). Third, tetrad analysis was carried out to
determine if the cloned gene was allelic to shr5. Strain SPDFa
(MATa shr5null), containing a disruption of SHR5, was crossed
with strain SN12 (MATa RAS2Val-19 shr5). A total of 76 com-
plete tetrads were analyzed for heat shock sensitivity, and no
recombinants exhibited the heat shock sensitivity characteristic
of RAS2Val-19 strains. Therefore, we conclude that the isolated
gene is SHR5.
shr5 fails to suppress hyperactive mutations downstream of
RAS. We carried out genetic studies to localize the site of
action of SHR5 in the Ras-adenylyl cyclase pathway (Table 2).
We first tested if SHR5 operates through the upstream regu-
lators of Ras function. Disruption of the GAPs encoded by
IRA1 or IRA2 (54) can activate Ras. The heat shock sensitivity
of an ira1null, an ira2null, or a RAS2Val-19 strain is attenuated in
an shr5null background. Disruption of SHR5 in a RAS2Val-19
cdc25null strain also attenuated its heat shock sensitivity. We
then determined if an SHR5 disruption can attenuate the heat
shock sensitivity created by hyperactivation of downstream el-
ements in the Ras-adenylyl cyclase pathway. BCY1 (56) en-
codes the regulatory component of the protein kinase A sub-
units encoded by the TPK genes (57), and its disruption results
in hyperactivation of the kinases leading to heat shock sensi-
tivity. A bcy1null shr5null strain remained heat shock sensitive in
the presence or absence of SHR5. Disruption of SHR5 also
failed to attenuate the heat shock sensitivity of wild-type
strains overexpressing either protein kinase A (TPK1) or ad-
enylyl cyclase (CYR1). Therefore, disruption of SHR5 blocks
Ras function but fails to block elements downstream of Ras.
shr5 attenuates hyperactive RAS2Val-19 in the absence of the
effector adenylyl cyclase. The severe growth defect resulting
from disruption of adenylyl cyclase in S. cerevisiae T158-5A1
can be rescued by overexpression of SCH9, a gene encoding a
protein kinase with homology to the TPK-encoded protein
kinases (55). For convenience, we refer to this strain as cyr1null
SCH91. We tested the consequence of overexpressing acti-
vated RAS2Val-19 in this strain and found that it leads not to
heat shock sensitivity but to a severe growth defect (Fig. 3,
sector 1) and a starvation sensitivity (29). Since adenylyl cyclase
is absent from this strain, it is unlikely that theRAS2Val-19-depen-
dent effects are mediated through the cyclic AMP (cAMP)
pathway. The growth defect resulting from overexpression of
RAS2Val-19 in a cyr1null SCH91 strain was suppressed by dis-
ruption of SHR5 (Fig. 3, sectors 1 and 2), whereas expression
of SHR5 by itself had no effect on cell growth (Fig. 3, sectors 3
and 4). The growth defect was also suppressed by overexpres-
sion of the GAP encoded by NF1 (1), therefore indicating that
the effect is through Ras (29). This result is consistent with
previous observations that NF1 can inhibit the function of
activated H-rasVal-12 (1). We observed similar results for star-
vation sensitivity, which can also be attenuated by disruption of
SHR5 or by overexpression of the NF1 gene (29). These ex-
periments indicate that shr5 can attenuate Ras function in the
absence of adenylyl cyclase.
shr5 affects the growth-promoting function of normal Ras.
We had established that disruption of SHR5 suppresses hyper-
active RAS2Val-19, but could not find any phenotypic effects of
disrupting SHR5 in a wild-type background, suggesting that
SHR5 does not play a role in the normal growth-promoting
function of Ras. To address this issue more critically, we
needed to test whether SHR5 played a role in promoting
growth when Ras was weakened mutationally. Whereas hyper-
activation of Ras leads to heat shock sensitivity (50, 58), loss of
Ras function manifests as a temperature sensitivity (57, 60).
Therefore, we tested whether disruption of SHR5 had any
effects in a ras1null or a ras2null background, using a tempera-
ture sensitivity assay (Fig. 4). Disruption of SHR5 in a ras1null
RAS2 background did not lead to any discernible phenotype.
In contrast, disruption of SHR5 significantly amplified the mild
FIG. 3. SHR5 attenuates RAS2Val-19 in the absence of the effector adenylyl
cyclase. The cyr12 strain, whose viability was rescued by overexpression of SCH9,
was transformed with the indicated plasmids. RAS2Val-19 was expressed from the
LEU2-based plasmid YEp112-RAS2Val-19. SHR5 was expressed from the TRP1-
based plasmid YCp22-SHR5. Transformants were streaked onto plates, and the
plates incubated at room temperature.
TABLE 2. Genetic analysis of SHR5a
Strain Relevant genotype 1SHR5 2SHR5
IR1DF ira1null shr5null 1 2
IR2DF ira2null shr5null 1 2
TKDF RAS2
Val-19
shr5null 1 2
TMDF cdc25null RAS2Val-19 shr5null 1 2
SPDFB bcy1null shr5null 1 1
SPDF shr5null TPK11 1 1
SPDF shr5null CYR11 1 1
a Dependence of heat shock sensitivities on SHR5. All strains used contained
disruptions of the SHR5 gene. These strains were transformed with plasmid
YCp22-SHR5 for expression of SHR5 (1SHR5) or the parental plasmid YC-
plac22 as a control (2SHR5). Heat shocks were performed as described in the
text. 1 and 2, maintenance or attenuation of heat shock sensitivity, respectively;
1, overexpression of the gene TPK1 or CYR1 from plasmid YEp13-TPK1 or
YEp13-CYR1, respectively.
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temperature-sensitive growth defect of ras2null mutants, such
that the double shr5null ras2null mutants did not grow at 368C
(Fig. 4, row 4). This result was confirmed in analysis of a cross
between an shr5null mutant and a ras2null mutant. In 10 com-
plete tetrads, only the eight double ras2null shr5null mutants
were temperature sensitive at 368C. Thus, Ras1 protein is un-
able to promote growth at 368C when SHR5 is absent.
To test whether SHR5 affected the growth-promoting func-
tion of a mutationally weakened Ras2 protein, we also dis-
rupted SHR5 in the STS1 strain carrying a RAS2 allele with a
mutation in the effector region (10, 46). This strain, which is
also ras1null, cannot grow at 378C but retains the ability to grow
at 348C. Disruption of SHR5 in this strain blocks the ability to
grow at 348C. This effect of the combined mutations was con-
firmed by tetrad analysis (29). SHR5 can, therefore, influence
the growth-promoting function of both Ras1 and Ras2 pro-
teins.
We next showed that loss of SHR5 function results in atten-
uation of the Ras-adenylyl cyclase pathway. Elements in this
pathway were tested to determine if they alter the increased
temperature sensitivity of the RAS1 ras2null shr5null strain. We
found that such cells transformed with a control plasmid or a
CDC25 expression plasmid remained temperature sensitive at
378C, whereas expression of RAS2, SHR5, or CYR1 was able to
reverse the temperature sensitivity (Fig. 5).
shr5mutants are defective in the membrane attachment and
palmitoylation of RAS2 proteins. The epistasis results sug-
gested that SHR5 might operate at the same level as Ras.
Therefore, we sought to determine whether the posttransla-
tional modification or membrane attachment of Ras proteins
was altered in shr5 mutants. We analyzed the membrane at-
tachment of Ras proteins by biochemical fractionation and
immunoblotting with anti-Ras antibodies (Fig. 6A). A signifi-
cant proportion of Ras2 proteins in Shr5 mutants is found in
the soluble fraction. This contrasts with the undetectable Ras2
protein from the soluble fraction in wild-type cells and the
much more severe mislocalization to the soluble fraction seen
in ram1 mutants. This partial mislocalization of Ras2 proteins
to the soluble fraction in Shr5 mutants was observed in re-
peated experiments.
We sought to determine whether the mislocalized protein
was processed in shr5 mutants. The Ras2 protein in shr5 mu-
tants is likely to be polyisoprenylated, since in other experi-
ments it clearly comigrated with fully processed Ras2 from
wild-type cells and did not comigrate with unprocessed Ras2
from ram1 mutants (29). (This difference is not evident in the
experiment depicted in Fig. 6, in which the proteins were
separated on a minigel of insufficient resolving capacity.) Then,
we decided to examine whether the mislocalization of Ras2
protein in shr5 mutants might be due to a defect in palmitoy-
lation of Ras2 protein. It has been established that the efficient
attachment and specific targeting to plasma membranes for
mammalian H-ras is dependent on this final processing step,
and similar results have been obtained for yeast Ras2 protein
(43). Therefore, we performed metabolic labeling with [3H]
palmitic acid and immunoprecipitated Ras2 proteins for anal-
ysis by SDS-PAGE and autoradiography. As seen in Fig. 6B,
there is a significant defect in the palmitoylation of Ras2 pro-
tein in shr5 mutants. The metabolically labeled extracts were
immunoblotted for the detection of Ras2 protein to show that
the amount of Ras2 protein did not differ substantially between
the wild-type and shr5 mutants (Fig. 6C). Results from Fig. 6B
and C are quantitated in Table 3.
We conclude from this series of experiments that Ras2 pro-
tein is mislocalized in shr5 mutants and has diminished palmi-
toylation.
Evidence that Shr5 is membrane associated and is not the
Ras protein palmitoyltransferase. We examined the subcellu-
lar localization of HA1 epitope-tagged Shr5 protein by bio-
FIG. 4. Increased temperature sensitivity of shr5null strains. The ras12 RAS2
SHR5 strain is ST-1 (row 1). The ras12 RAS2 shr52 strain is STDF (row 2). The
RAS1 ras22 SHR5 strain is KP-2 (row 3). The RAS1 ras22 shr52 strain is KPDF
(row 4). Temperature sensitivity assays were carried out as described in the text.
Triplicate plates were incubated at room temperature (A), at 368C (B), or at
388C (C).
FIG. 5. Reversal of temperature sensitivity of RAS1 ras22 shr52 strain RS81-1B by elements of the RAS-adenylyl cyclase pathway. The indicated strains were
transformed with plasmids expressing various indicated genes (see Table 1) (A). Transformed cells were streaked onto duplicate plates and then incubated at 308C (B)
and 378C (C).
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chemical fractionation and immunoblotting (Fig. 7A). HA1-
tagged GST and Ste18 protein (18) were used as controls for
cytosolic and membrane-bound proteins, respectively. The
HA1-Shr5 protein was detected as an '35-kDa band only in
the particulate fraction. Hence, Shr5 protein may be a mem-
brane-bound protein where it could directly participate in the
membrane targeting of Ras proteins. Incidentally, HA1-Shr5
migrates significantly more slowly than predicted from its mass
('28.7 kDa). Recombinant Shr5 expressed in bacteria also
migrates slowly (29).
To determine if shr5 mutants are defective for Ras protein
palmitoyltransferase activity, we performed an in vitro assay
for palmitoylation of Ras proteins according to the procedure
developed by Magee and coworkers (38). Whole-cell extracts
were prepared from strains which overexpressed Ras2 protein
and were incubated with [3H]palmitate in the presence of co-
factors to promote in vitro palmitoylation of proteins. As
shown in Fig. 7B, shr5 mutants display as many palmitoylated
protein bands as do wild-type cells. In fact, for the shr5mutant,
there is increased labeling of a band that migrates at the mo-
lecular mass predicted for Ras2, 42 kDa, and that is only
present in experiments performed with strains overexpressing
Ras2 protein. This effect of increased labeling of the 42-kDa
protein in shr5 mutants is more pronounced with shorter in-
cubation times and with lower amounts of added extract (29).
This result indicates that in shr5 mutants, there is a larger pool
of nonpalmitoylated Ras2 protein available for palmitoylation
in the in vitro assay. This is consistent with our findings of a
defect in palmitoylation of Ras2 protein by metabolic labeling.
There is certainly no evidence for a defect in protein palmi-
toylation by this in vitro assay.
Evidence that Shr5 interacts in vivo with nonpalmitoylated
and with completely unprocessed Ras2 proteins. The results
from the previous section suggested that SHR5 does not en-
code the Ras palmitoyltransferase. To test whether the major
phenotypic effect of SHR5 is mediated by its effects on Ras2
palmitoylation, we asked whether SHR5 could interact genet-
ically with RAS2 alleles missing the unique cysteine palmitoy-
lation site at position 318 (6, 27, 44). Indeed, we found by a
temperature sensitivity assay that the absence of SHR5 blocked
the growth of RAS2Ser-318 strains at 388C (Fig. 8). This effect is
specific to the Ras-adenylyl cyclase pathway since it can be
suppressed by overexpression of protein kinase A. We showed
similar results for the hyperactivated RAS2Val-19Ser-318 allele
which, although attenuated, is still capable of producing a
significant heat shock-sensitive phenotype (44). We found that
the shr5null mutation suppressed the heat shock sensitivity in-
duced by this nonpalmitoylatable version of hyperactive RAS2
(29). Thus, the ability of the shr5 deletion to suppress hyper-
active RAS2 does not depend on its palmitoylation status.
We decided to take this analysis one step further and ask if
the ability of SHR5 to influence Ras function required that Ras
proteins be farnesylated. RAS2 alleles encoding a serine in-
stead of a cysteine at position 319 within the CAAX box are
blocked for farnesylation but can supply essential function if
FIG. 6. (A) shr5 mutants defective in membrane localization of Ras protein.
Fractionation of yeast extracts into soluble (S) and membrane (P) fractions and
detection of Ras proteins by Western blot analysis were performed as described
in the text. The wild-type (wt) strain is SP1. The shr5 strain is SPDF. The ram1
strain is STS11 (45). The arrow indicates the approximately 42-kDa band for Ras
protein. (B and C) shr5 mutants defective for palmitoylation of Ras protein. (B)
Autoradiographic detection of immunoprecipitated Ras2 protein labeled with
[3H]palmitic acid; (C) Western blot quantitation of Ras2 protein for the corre-
sponding 3H-labeling experiments. The wild-type (wt) cell line is SP1. The shr5-1
strain is RS44-5B. The Dshr5 strain is SPDF. Ras2 protein was expressed from a
galactose-inducible plasmid, pGAL10-RAS2 (31).
TABLE 3. Palmitoylation of overexpressed Ras2 proteins in
shr5 strainsa
Strain Plasmid
Amt of protein
Efficiency
Total Palmitoylated
SP1 YEp51-RAS2 11,567 5,893 0.509
shr5-1 YEp51-RAS2 11,975 44 0.00367
SPDF YEp51-RAS2 6,769 336 0.049
SP1 YEp51 Undetectable Undetectable
a Identical amounts of protein extracts (prepared from [3H]palmitate-labeled
yeast strains) were immunoprecipitated, resolved by SDS-PAGE, and subjected
to Western blot (immunoblot) and autoradiographic analysis as described in
Materials and Methods. The quantitation of Ras2 protein and palmitoylated
Ras2 protein was by densitometry, and the results are expressed as relative units.
The palmitoylation efficiency was calculated by dividing the units of palmitoy-
lated Ras2 by the units of Ras2 protein.
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they are overexpressed (12). We have found that the nonfar-
nesylated RAS2Val-19Phe-319 allele can promote growth at room
temperature and weakly at higher temperatures (10). To test if
SHR5 influenced the ability of nonfarnesylated Ras2 protein to
promote growth in this background, we deleted SHR5 in a
ras1null RAS2Val-19Phe-319 strain and examined its growth prop-
erties (Fig. 8). Deletion of SHR5 blocks the ability of the strain
to grow at 348C. This effect is specific to the Ras-adenylyl
cyclase pathways, since it can be reversed by overexpression of
protein kinase A. The synergistic temperature-dependent
growth defect was also confirmed by analysis of a cross be-
tween a shr5 strain and a ras1null RAS2Val-19Phe-319 strain (29).
The ability of Shr5 to influence the function of Ras does not
appear to depend on its modification status.
DISCUSSION
We have isolated a novel gene whose product is involved in
Ras function. Although disruption of SHR5 in wild-type S.
cerevisiae did not lead to any apparent phenotypic defects, it
did suppress RAS2Val-19 cells and did influence the normal
growth-promoting function of strains in which Ras was atten-
uated.
By genetic analyses, we deciphered where SHR5 functions
relative to RAS. Disruption of SHR5 suppressed the hyperac-
tivation of the Ras-adenylyl cyclase pathway in ira1null, ira2null,
and RAS2Val-19 strains. We interpret this to mean that Shr5
functions independently of the GAPs. In addition, disruption
of SHR5 attenuated RAS2Val-19 regardless of the presence or
absence of the guanine nucleotide exchange factor encoded by
CDC25. This indicates that Shr5 does not regulate Ras func-
tion by mediating its interaction with Cdc25. These genetic
experiments indicate that Shr5 does not function through the
upstream Ras regulators, leading us to test elements down-
stream of the Ras pathway. It was found that disruption of
SHR5 failed to attenuate downstream activation of the adeny-
lyl cyclase pathway caused by overexpression of the CYR1 or
TPK1 gene or by disruption of the negative regulator of protein
kinase A encoded by BCY1. We showed that the attenuation of
Ras function in shr5mutants can be relieved by overexpression
of downstream elements in the Ras pathway. Taken together,
these studies place the function of Shr5 at the level of Ras and
upstream of adenylyl cyclase.
We then showed by a novel assay that SHR5 disruptants
exhibit attenuated Ras pathway function even in the absence of
adenylyl cyclase. This assay was based on the observation that
overexpression of RAS2Val-19 conferred a phenotype in a
cyr1null strain whose viability had been rescued by overexpres-
sion of a downstream kinase encoded by SCH9 (55). cyr1null
SCH91 RAS2Val-191 cells are not heat shock sensitive but are
growth inhibited and starvation sensitive. The observation of a
RAS2Val-19-dependent phenotype in a cyr1null strain supports
the alternate-Ras pathway hypothesis that was originally pro-
posed to explain the lethality of a rasnull strain versus the viable
but sick cyr1null strain (60). Disruption of SHR5 attenuated the
RAS2Val-19 phenotype in this strain, indicating that Shr5 func-
tions at the level of Ras and not on adenylyl cyclase or its
downstream targets.
We investigated the possibility that Shr5 is involved in Ras
modification, since previously isolated suppressors of
RAS2Val-19 had defects in genes encoding the subunits of Ras
farnesyltransferase, ram1 and ram2. Indeed, fractionation
studies indicate that shr5 mutants are partially defective in Ras
localization; a larger portion of Ras in shr5mutants is cytosolic
than in wild-type cells, in which Ras is predominantly localized
to the membrane. In addition, there is a defect in the palmi-
toylation of Ras protein in shr5 mutants. The comigration of
Ras protein from shr5 mutants with the proteolytically pro-
cessed Ras protein from wild-type cells makes it unlikely that
shr5 mutants are defective in farnesylation, since mutants de-
fective in farnesylation display altered migration of Ras pro-
teins on SDS-PAGE.
The defect in palmitoylation of Ras suggests that SHR5
encodes a component of a Ras palmitoyltransferase. There-
fore, we tested if extracts prepared from shr5 mutants are
defective for palmitoylation of endogenous proteins, including
Ras. By a cell-free assay, no palmitoylation defect was ob-
served in shr5 mutants. In fact, in such cells we observed
increased labeling of a band that coincides with Ras2, perhaps
because, as we demonstrated, shr5 mutants have an increased
amount of unpalmitoylated Ras that can serve as a substrate
FIG. 7. (A) Membrane or cytoskeletal association of Shr5 protein. Soluble
(S) and insoluble (P) fractions of cells expressing HA1 epitope-tagged forms of
GST, Ste18, or Shr5 protein were prepared as described in the text. For Western
blot analysis, antibody 12CA5 was used for detection of the HA1 epitope. (B)
Comparison of in vitro palmitoylation of proteins in extracts prepared from
wild-type (wt) and shr5 mutant cells. Extracts were prepared from wild-type
strain SP1 and shr5 mutant strain SPDF; both were transformed by the high-
copy-number plasmid expressing Ras2 and assayed according to the method
described by Magee et al. (38). The arrow indicates an approximately 42-kDa
band corresponding to Ras2 protein. This band is not present in untransformed
cells.
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for the in vitro palmitoylation assay. There was no apparent
alteration in the in vitro labeling of other proteins by palmi-
toylation. SHR5 is, therefore, unlikely to encode a major cel-
lular palmitoyltransferase. We do not believe that SHR5 en-
codes a Ras-specific palmitoyltransferase, because the ability
of the shr5 disruption to suppress hyperactive Ras2 or influ-
ence the growth-promoting function of Ras2 does not depend
on the palmitoylation status of the Ras protein. In fact, the
ability of Shr5 to influence Ras function did not even require
that Ras proteins be polyisoprenylated. Therefore, Shr5 can
functionally interact with Ras regardless of its modification
state.
To date, the data suggest but do not prove that Shr5 is
specific for Ras. First, in the comparison of shr5 mutants and
wild-type cells, the in vitro palmitoylation defect appeared to
be specific only for Ras but not other protein bands (Fig. 7B),
even though similar levels of Ras protein were expressed (Fig.
6C). However, it is possible that Shr5 modifies the palmitoy-
lation of other proteins that are expressed at levels too low to
detect in this assay. Second, there are other G proteins in S.
cerevisiae that might be affected by Shr5 function: Rsr1 (Bud1)
(9, 48), which is involved in budding, and Ste18 (18, 59), which
is involved in mating. We found that shr5null mutants are nei-
ther budding nor mating defective (29), suggesting that the
absence of Shr5 did not attenuate the activities of these other
G proteins. It remains possible that Shr5 has wider functions,
even though there are no apparent differences between shr5null
and wild-type cells. The role of SHR5 becomes manifest only
under synthetic conditions, such as in our case, when mutant
forms of RAS are being used. It is possible that other roles for
Shr5 can be discerned under other synthetic conditions. Al-
though the evidence indicates that Shr5 might be specific for
Ras, more confirmatory work is necessary.
What might be the function of Shr5? Although more com-
plex models are possible, the most compelling indication of
Shr5 function is suggested by its ability to influence localization
and palmitoylation of Ras. Our data are consistent with a
model in which Shr5 promotes attachment to the membrane
and the defect in palmitoylation is a secondary consequence of
this defect in membrane attachment. This is consistent with
our observation of no defect in palmitoyltransferase activity
per se. The ability of Shr5 to influence completely unmodified
Ras proteins suggests that even for the function of nonmodi-
fied Ras, at least some proper localization to the membrane is
important, and this is supported by the recent report of De-
schenes and coworkers (40). Membrane localization might be
important if the interaction of Ras with either active Cdc25
protein or effector took place exclusively in the membranes.
The ability of Shr5 to functionally interact with unprocessed
Ras and to influence Ras localization to the membrane sug-
gests that it might be involved in the plasma membrane tar-
geting of Ras proteins (7, 51) and that its function is not solely
FIG. 8. SHR5 interacts genetically with nonpalmitoylated RAS2Ser-318 and nonfarnesylated RAS2Val-19Phe-319 mutants. The RAS2Ser-318 and RAS2Ser-318 shr5null
strains are LI-1-3A and LIDF, respectively. The RAS2Val-19Phe-319 and RAS2Val-19Phe-319 shr5null strains are STS3 and STS3DF, respectively. SHR5 was expressed from
plasmid YCp22-SHR5. Temperature sensitivity assays were carried out as described in the text.
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dependent on recognition of the lipid groups. Thus far, we
have not detected interaction of Shr5 with Ras by the two-hyrid
method (17), thus suggesting that Shr5 functions as an element
in a protein complex, that its effects on Ras is indirect, or that
its interaction is too transient to observe. The isolation of
proteins that function in concert with or that directly interact
with Shr5 should further our understanding of how Ras local-
ization is controlled and how this might impact Ras function.
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